ArticleScientific reports2025
Analysis of time-fractional cancer-tumor immunotherapy model using modified He-Laplace algorithm.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer encompasses various diseases characterized by the uncontrolled growth of abnormal cells, which can invade healthy tissues and spread throughout the body, making it the second leading cause of death worldwide. This study presents a fractional cancer treatment model with immunotherapy to enhance understanding of cancer's mathematical framework and behavior. The model comprises fractional differential equations analyzed using the Caputo-fractional derivative, aiming to control cancer growth while considering cell population metrics. A framework integrating various homotopies and Laplace transforms is developed to explore cancer's complexities. Simultaneous solution profiles for effector immune cells and tumor cells illustrate their mutual influence. The model examines parameters such as the death rate of immune cells, natural tumor growth rate, rate of immune cells killing fractional tumor cells and numerous others graphically for clarity. The fractional parameter β is visually represented through 2D, 3D, and contour plots. This comprehensive analysis validates the proposed approach, suggesting its applicability to other complex cancer treatment models for better decision-making in cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.